TrimRx's Blog
Survodutide for MASH: Treating Fatty Liver Disease and Obesity Together
Survodutide is being studied for a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis), and its early results are among the most promising in…
Is Orforglipron FDA Approved Yet? Timeline and What to Expect
Yes. Orforglipron was approved by the FDA on April 1, 2026, and is sold under the brand name Foundayo. It’s approved for adults with…
Orforglipron Side Effects: What Early Studies Report
Orforglipron, now FDA approved and sold as Foundayo, has a side-effect profile that looks a lot like injectable GLP-1 drugs despite being a pill:…
How Much Weight Can You Lose on CagriSema? Trial Results Explained
In its main obesity trial, CagriSema produced an average weight loss of about 22.7% over 68 weeks, which is among the highest seen for…
CagriSema Side Effects: What the Trials Show
CagriSema’s side effects are mostly gastrointestinal, and while they’re common, the large majority are mild to moderate and fade over time. In the phase…
Bimagrumab and GLP-1s: The Drug Studied to Preserve Muscle During Weight Loss
Bimagrumab is an unusual entry in the weight-loss world: it’s not a GLP-1 drug at all, but an antibody being studied to solve one…
What Is Petrelintide? The Amylin Drug Being Studied for Weight Loss
Petrelintide is an investigational weight-loss injection that works through amylin, a satiety hormone separate from the GLP-1 pathway, and its main selling point is…
What Is VK2735? Viking’s Oral and Injectable Obesity Drug
VK2735 is an investigational obesity drug from Viking Therapeutics with a notable flexibility: it’s being developed in both an injectable form and an oral…
What Is Mazdutide? The GLP-1/Glucagon Drug from Lilly and Innovent
Mazdutide is a weekly weight-loss injection that’s notable for a milestone: it’s the world’s first approved drug to combine GLP-1 and glucagon activity in…
